Bottom line
Is VRKSX a good fund? The bottom line
VRKSX is the Class R6 share class of Virtus KAR Small-Mid Cap Growth Fund, a managed small-cap mutual fund from Virtus.
Its expense ratio is 0.89% — about $89 a year on every $10,000 invested, cheaper than 63% of small-cap funds we track.
It returned −8.2% over one year, +0.5% a year over five years (as of Dec 31, 2025, per its prospectus).
With $6.4 million in net assets and 27 holdings, its largest position is West Pharmaceutical Services Inc (6.4%) and the top 10 make up 49.4% of the portfolio.
What stands out
- No front-end sales load
What to watch
- 5-year return in the bottom quarter of its category
- Small fund ($6.4 million) — small funds are likelier to close
Updated Nov 19, 2026
What VRKSX invests in
The fund has an investment objective of long-term capital appreication.
The fund pursues long-term capital appreciation in the small and medium market capitalization sectors while seeking to incur less risk than the small- and mid-cap growth markets. The fund invests in a select group of small and mid capitalization companies believed by the subadviser to possess sustainable competitive advantages at prices the subadviser deems attractive. The investment strategy emphasizes companies the subadviser believes to have a sustainable competitive advantage, strong management and low financial risk and to be able to grow over market cycles. Although the fund invests primarily in U.S. companies, it may invest in foreign securities and depositary receipts. Under normal circumstances, the fund invests at least 80% of its assets in common stocks of small- and mid-market capitalization companies. As of the date of this Prospectus, the funds subadviser considers small…
From the fund's prospectus (filed Jan 22, 2026).
VRKSX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| VRKSX | −8.2% | +0.5% | — |
| Small-Cap median | +7.6% | +7.0% | +9.2% |
Source: Fund prospectus, as of Dec 31, 2025
What VRKSX costs
On a $10,000 investment, VRKSX's 0.89% expense ratio costs about $89 a year. The prospectus estimates $2,160 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.
VRKSX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | West Pharmaceutical Services Inc WST | 6.36% |
| 2 | Hinge Health Inc HNGE | 6.03% |
| 3 | Aaon Inc AAON | 5.43% |
| 4 | Heico Corp HEI/A | 5.41% |
| 5 | Teledyne Technologies Inc TDY | 4.83% |
| 6 | Lemaitre Vascular Inc LMAT | 4.68% |
| 7 | Ul Solutions Inc ULS | 4.22% |
| 8 | Simpson Manufacturing Co Inc SSD | 4.22% |
| 9 | Healthequity Inc HQY | 4.20% |
| 10 | Sharkninja Inc SN | 3.96% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 49.4% of the fund. See all top 25 holdings and asset mix →